Design: Retrospective real-world cohort study using the Netherlands Cancer Registry, 2010-2022
Population: 5,632 patients with stage M1a non-small-cell lung cancer receiving systemic treatment: 2,701 contralateral lung metastases, 2,590 pleural metastases, 341 both
Primary outcome: Two-year overall survival by M1a descriptor and treatment type
Effect: Contralateral lung metastases 26.9% (chemotherapy), 49.5% (immunotherapy), 40.4% (chemo-immunotherapy); pleural metastases 18.5%, 41.6%, 28.6%; both 12.1%, 31.1%, 25.0%. Difference present irrespective of systemic treatment

The ninth edition of the TNM staging system keeps pleural and contralateral pulmonary metastases together in M1a, which implies they carry similar prognostic weight. This analysis of the Netherlands Cancer Registry tested that in 5,632 patients with M1a non-small-cell lung cancer treated systemically between 2010 and 2022: 2,701 with contralateral lung metastases, 2,590 with pleural metastases, and 341 with both.

The descriptors separated consistently. Two-year overall survival with contralateral lung metastases was 26.9% on chemotherapy, 49.5% on immunotherapy alone and 40.4% on chemo-immunotherapy. With pleural metastases it was 18.5%, 41.6% and 28.6%. Patients with both did worst: 12.1%, 31.1% and 25.0%. The gap held across every treatment type, which is what distinguishes a prognostic difference from a treatment interaction.

Some of this is confounding — pleural metastases were commoner in men, in patients with worse performance status, and in those given single-agent immunotherapy, all of which predict worse survival independently. But the consistency across three treatment strategies makes a purely artefactual explanation harder to sustain.

What changes now is the conversation rather than the treatment. A patient with a malignant pleural effusion and a patient with a contralateral nodule are both M1a, and telling them the same thing about prognosis is not supported by these data.

Record which M1a descriptor is present, not just the stage
Adjust prognostic discussion accordingly — the two-year survival gap is 8 percentage points or more
Note that those with both descriptors fare substantially worse than either alone
Do not alter systemic treatment choice on this; the difference was present under every regimen
Remember the confounding by performance status and sex when quoting these figures to an individual

Why it matters

It shows a staging category doing what staging categories are meant to prevent — grouping two different prognoses under one label.

The statistics, in plain English

These are unadjusted two-year survival proportions from a registry, so the gap between groups includes whatever else differs between them — and the paper states that performance status and treatment allocation did differ. The consistency across all three treatment strategies is the strongest argument that something real underlies it, because confounding would have to operate identically in each. With 2,590 and 2,701 patients the confidence intervals are narrow, but narrow intervals around a confounded estimate are still confounded.